Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Znomics, which develops new pharmaceutical products for treatment of human disorders and diseases, has appointed Bruce Beutel as its new chief scientific officer, succeeding Roger Cone, effective June 16, 2008.
Subscribe to our email newsletter
Dr Cone has accepted the position of chairman of the department of molecular physiology and biophysics at Vanderbilt University Medical Center, starting in August, but will continue as a scientific consultant to Znomics and as an active member of the company’s board of directors.
From 1995 to 2007, Dr Beutel was with Abbott Laboratories, last serving as senior director. At Abbott, Dr Beutel was also director of biology, metabolic disease research; senior project leader, infectious disease research; and project leader, advanced technology.
Dr Beutel earned his doctor of philosophy degree in molecular biology from the University of Wisconsin-Madison, and his Bachelor of Science degree in biology from the University of Chicago.
Richard Sessions, CEO of Znomics, said: “Dr Beutel’s broad drug discovery expertise and experience includes biological research, target and lead identification, hit-to-lead chemistry, lead compound optimization, and advancement of preclinical drugs into human clinical studies.”